Evidence map›Paper›PMID 34337571›Full record

ArticleHeart rhythm O22021

Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.

Francis E Ugowe, Anne S Hellkamp, Allen Wang, Richard C Becker, Scott D Berkowitz, Günter Breithardt, Keith A A Fox, Jonathan L Halperin, Graeme J Hankey, Kenneth W Mahaffey and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart rhythm O2, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 4 countries.

Francis E UgoweDuke University Medical Center, Duke University School of Medicine, Durham, North Carolina.
Anne S HellkampDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Allen WangDuke Center for Atrial Fibrillation, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Richard C BeckerUniversity of Cincinnati College of Medicine, Cincinnati, Ohio.
Scott D BerkowitzBayer U.S. LLC, Parsippany, New Jersey.
Günter BreithardtHospital of the University of Münster, Münster, Germany.
Keith A A FoxUniversity of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Jonathan L HalperinMount Sinai School of Medicine, New York, New York.
Graeme J HankeySchool of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia.
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University, School of Medicine, Stanford, California.
Christopher C NesselJanssen Research & Development, Raritan, New Jersey.
Daniel E SingerMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Manesh R PatelDuke University Medical Center, Duke University School of Medicine, Durham, North Carolina.
Jonathan P PicciniDuke University Medical Center, Duke University School of Medicine, Durham, North Carolina.
of the ROCKET AF Steering Committee and Investigators
Clinical Research Institute · USDuke Medical Center · USBayer (United States) · USDuke University · USEdinburgh Royal Infirmary · GBHarvard University · USIcahn School of Medicine at Mount Sinai · USJanssen (United States) · USStanford University · USUniversity of Cincinnati Medical Center · USUniversity of Münster · DEUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF).

objectivesDetermine if the increased risk of stroke observed in patients with AF and diabetes is restricted to those treated with insulin.

methodsWe analyzed the association between diabetes and treatment and the occurrence of stroke/systemic embolism, myocardial infarction (MI), all-cause death, vascular death, composite outcomes, and bleeding risk in the ROCKET AF trial.

resultsIn a cohort of 14,264 patients, there were 40.3% (n = 5746) with diabetes, 5.9% (n = 842) on insulin, 18.9% (n = 2697) on oral medications, and 11.9% (n = 1703) diet-controlled. Compared to those without diabetes, patients with non-insulin-treated diabetes had increased risks of stroke (hazard ratio [HR] 1.33, 95% confidence interval [CI] 1.06-1.68), MI (HR 1.64, 95% CI 1.17-2.30), all-cause death (HR 1.26, 95% CI 1.08-1.46), vascular death (HR 1.33, 95% CI 1.11-1.60), and composite outcomes (HR 1.37, 95% CI 1.18-1.157). Patients with insulin-treated diabetes had a significantly higher risk of MI (HR 2.31, 95% CI 1.33-4.01) and composite outcomes (HR 1.57, 95% CI 1.19-2.08) compared to those without diabetes. There were no significant differences between insulin-treated and non-insulin-treated diabetes for any outcome.

conclusionAmong patients with AF and diabetes, there were no significant differences in outcomes in insulin-treated diabetes compared to non-insulin-treated diabetes.

Indexed as

Atrial fibrillationDiabetesRivaroxabanStrokeWarfarin

Identifiers

PMID34337571
PMCPMC8322824
OpenAlexW3154538869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.